# A Multicenter Study Evaluating the Safety and Tolerability of Intravenous rhMBL in Liver Transplant Recipients.

> **NCT00415311** · PHASE1 · TERMINATED · sponsor: **Enzon Pharmaceuticals, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Liver Transplantation

## Interventions

- **DRUG:** Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)
- **DRUG:** Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)
- **DRUG:** Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)

## Key facts

- **NCT ID:** NCT00415311
- **Lead sponsor:** Enzon Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12
- **Primary completion:** 2009-06
- **Final completion:** 2009-12
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Sponsor decision to terminate the study
- **Last updated:** 2011-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00415311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00415311, "A Multicenter Study Evaluating the Safety and Tolerability of Intravenous rhMBL in Liver Transplant Recipients.". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00415311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*